Chicago、ILにおける卵巣がんの臨床試験
Chicagoとその周辺地域（約30マイル以内）の拠点で、卵巣がんに関する36件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
被験者募集中第1/2相
- Research Site, Chicago
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
被験者募集中第2/3相
- Northwestern University, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- Northwestern Medicine Cancer Center Old Irving Park, Chicago
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
被験者募集中第2相
- Mount Sinai Hospital Medical Center, Chicago
- Northwestern University, Chicago
- John H Stroger Jr Hospital of Cook County, Chicago
- 他3件
A Study of PHST001 in Advanced Solid Tumors
被験者募集中第1相
- University of Chicago Medical Center, Chicago
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
被験者募集中第1相
- University of Chicago Hospital, Chicago
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
被験者募集中第2相
- University of Illinois Cancer Center, Chicago
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer
被験者募集中第1相
- University of Chicago Medical Center /ID# 278295, Chicago
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
被験者募集中観察研究
- University of Chicago, Chicago
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
被験者募集中第2相
- Rush Md Anderson Cancer Center /ID# 274926, Chicago
- University of Chicago Medical Center /ID# 274796, Chicago
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
被験者募集中第1/2相
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
- University of Chicago Medical Center, Chicago
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
被験者募集中第3相
- Northwestern Memorial Hospital, Chicago
- Rush University Medical Center, Chicago
- The University of Chicago Medicine, Chicago
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
被験者募集中第1相
- Northwestern University Feinberg School of Medicine, Chicago
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
被験者募集中第3相
- The University of Chicago Medicine, Chicago
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
被験者募集中第2相
- University of Chicago, Chicago
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
被験者募集中第1相
- University of Illinois Cancer Center, Chicago
- University of Chicago Medicine, Chicago
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
被験者募集中第2相
- University of Chicago, Chicago
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
被験者募集中第1相
- University of Chicago Medical Center, Chicago
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
被験者募集中第1/2相
- Lurie Children's Hospital-Chicago, Chicago
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
被験者募集中
- Northwestern University, Chicago
- Rush MD Anderson Cancer Center, Chicago
- University of Illinois, Chicago
- 他2件
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
被験者募集中第3相
- John H Stroger Jr Hospital of Cook County, Chicago
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- 他1件
A Trial to Evaluate Safety, Tolerability, and Preliminary Efficacy of Misetionamide (GP-2250) as Monotherapy or in Combination With Gemcitabine
被験者募集中第1相
- Rush University Medical Center, Chicago
Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer
被験者募集中第2相
- The University of Chicago Medical Center, Chicago
An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib
被験者募集中第2相
- Northwestern Memorial Hospital, Chicago
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
被験者募集中第1相
- UChicago Medicine - River East, Chicago
- The University Of Chicago, Chicago
- University of Chicago Medical Center, Chicago
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
被験者募集中第1/2相
- Northwestern University, Chicago
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
被験者募集中第1/2相
- Northwestern Memorial Hospital, Chicago
Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment)
被験者募集中
- Northwestern University, Chicago
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
被験者募集中第1/2相
- University of Chicago Medical Center, Chicago
TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention
被験者募集中
- UChicago Medicine, Chicago
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
被験者募集中第1/2相
- University of Chicago Medical Center, Chicago
Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy
被験者募集中
- Northwestern Memorial Hospital, Chicago
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
被験者募集中第1相
- The University of Chicago Comprehensive Cancer Center, Chicago
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
被験者募集中第2相
- University of Chicago Medical Center, Chicago
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Chicago
Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
被験者募集中観察研究健康なボランティア歓迎
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
被験者募集中第2相
- Northwestern University, Chicago
他の都市における卵巣がんの試験
- Houston, TX89件の研究
- New York City, NY69件の研究
- Boston, MA61件の研究
- Los Angeles, CA50件の研究
- Nashville, TN49件の研究
- Arlington, VA46件の研究
- Philadelphia, PA44件の研究
- Columbus, OH39件の研究
- St. Louis, MO38件の研究
- San Antonio, TX31件の研究
- Cleveland, OH30件の研究
- Pittsburgh, PA30件の研究
Chicagoにおける他の研究
- 非小細胞肺癌61件の研究
- 乳がん59件の研究
- がん（全種類）51件の研究
- 転移性癌45件の研究
- 前立腺がん45件の研究
- 肺がん41件の研究
- 肥満症41件の研究
- 大腸癌34件の研究
- 脳卒中34件の研究
- 心不全31件の研究
- 過体重29件の研究
- 頭頸部扁平上皮癌26件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。